Predicting treatment outcome in classical Hodgkin lymphoma: genomic advances

Table 6 New agents for Hodgkin lymphoma currently under clinical development

Target	Agent	Phase	Response (PR+CR) (%)	Reference(s)
CD30	Brentuximab, Vedotin	I	50	[94]
CD20	Rituximab	II	22	[95]
mTOR	Everolimus	II	47	[96]
JAK2	SB1518	I	-	[97]
HDACs	LBH 589	II	26	[98]
	SAHA	II	4	[99]
	MGCD0103	II	30	[100]
AKT	MK2206	I	-	-
NF-kB	Bortezomib	II	7	[101]
Target unknown	Lenalidomide	II	13 to 17	[102, 103]

CR, complete response; HDACs, histone deacetylases; JAK2, Janus kinase 2; mTOR, mammalian target of rapamycin; NF, nuclear factor; PR, partial response.

ISSN: 1756-994X